Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139660 | 0.87 | BDKRB1 (0.79) | BDKRB1 | |
| SCHEMBL4134531 | 0.86 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL3994184 | 0.86 | BDKRB1 (0.84) | BDKRB1 | |
| SCHEMBL4469183 | 0.86 | BDKRB1 (0.78) | BDKRB1 | |
| SCHEMBL4000303 | 0.85 | BDKRB1 (0.83) | BDKRB1 | |
| SCHEMBL3995046 | 0.85 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL4477079 | 0.85 | BDKRB1 (0.86) | BDKRB1 | |
| SCHEMBL3991731 | 0.85 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL3995769 | 0.85 | BDKRB1 (0.77) | BDKRB1 | |
| SCHEMBL3998597 | 0.85 | BDKRB1 (0.94) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | claimed |
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
| EP-1606288-A1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | LABORATOIRES FOURNIER S.A. (FR) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004087700-A1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | LABORATOIRES FOURNIER S.A. (FR) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | BDKRB1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.